

# Integrated Organ Support Therapies Market to Reach \$6.69 Bn by 2033, Growing at 5.6% CAGR | DataM Intelligence

*The Integrated Organ Support Therapies Market is expanding steadily, driven by demand for advanced ICU technologies and multi-organ support in critical care.*

NEW YORK, NY, UNITED STATES, June 19, 2025 /EINPresswire.com/ -- Market Overview -

[Integrated Organ Support Therapies Market](#) are revolutionizing critical care by providing comprehensive, multi-organ support systems to patients

suffering from life-threatening, multi-organ failure. These therapies integrate mechanical support for organs such as the liver, lungs, kidneys, and heart, aiming to stabilize and improve the clinical outcomes in critically ill patients. As the burden of chronic diseases and critical conditions continues to rise, healthcare systems are increasingly turning to integrated

“

Integrated Organ Support Therapies are transforming critical care by enabling multi-organ support systems that improve survival and recovery in complex ICU patients.”

*DataM Intelligence*

technologies that can manage complex cases with greater precision and efficiency. In 2024, the global market for IOST reached US\$ 4.11 billion and is projected to hit US\$ 6.69 billion by 2033, growing at a steady CAGR of 5.6% over the forecast period (2025–2033).


Get Latest Sample Report :

<https://www.datamintelligence.com/download-sample/integrated-organ-support-therapies-market>

Market Drivers are ;

Rising incidence of chronic conditions such as diabetes, sepsis, and kidney and liver failure.

Growing demand for critical care technologies that manage multiple organ dysfunction



simultaneously.

Technological advancements in extracorporeal life support and organ perfusion systems.

Increasing geriatric population with comorbidities requiring multi-organ monitoring and support.

Expanding investment in advanced ICU infrastructure and acute care solutions.

Favorable reimbursement scenarios and regulatory support for life-sustaining therapies.

Key Players in the Market are ;

The Integrated Organ Support Therapies Market is driven by established medical device companies and innovative startups focused on critical care innovations:

Emulate, Inc.

Baxter International

Fresenius Medical Care AG

Getinge AB

LivaNova, Inc.

Asahi Kasei Corporation

ADVITOS GmbH

NIHON KOHDEN CORPORATION

Vapotherm

Fisher & Paykel Healthcare Limited

These players are enhancing their portfolios with solutions that address liver dialysis, renal replacement therapy, ECMO (Extracorporeal Membrane Oxygenation), and respiratory support—all within unified platforms.

Market Segmentation :

By Modality

Continuous Renal Replacement Therapy (CRRT)  
Extracorporeal Membrane Oxygenation (ECMO)  
Liver Support Therapy  
Combined Organ Support Therapy

By Organ Support Type

Renal  
Hepatic  
Respiratory  
Cardiovascular  
Multi-organ

By End User

Hospitals  
Specialty Clinics  
Ambulatory Surgical Centers  
Academic & Research Institutes

Latest News of USA -

In May 2024, Baxter International partnered with multiple U.S. health systems to pilot its integrated kidney-liver support system for ICU patients.

The FDA issued new guidance in September 2024 to expedite approvals for multi-organ extracorporeal support devices.

NIHON KOHDEN USA launched a centralized monitoring platform for multi-organ function in critical care units.

Latest News of Japan -

Asahi Kasei Corporation announced in June 2024 its new liver support therapy unit received PMDA approval for expanded clinical applications.

Japan's Ministry of Health launched a funding initiative in 2024 to upgrade ICUs in rural hospitals with integrated organ support capabilities.

In November 2024, Fresenius Japan rolled out its advanced CRRT platform with multi-parameter integration for acute care hospitals.

Recent Key Developments are ;

ADVITOS GmbH expanded clinical trials in Europe and Asia for its ADVOS multi-organ support platform.

LivaNova launched a next-generation ECMO device tailored for long-term respiratory and cardiac support.

Emulate, Inc. introduced an organ-on-chip solution aimed at improving preclinical validation for multi-organ dysfunction treatment.

Getinge AB received CE approval for a combined liver-kidney support module compatible with its existing ICU platforms.

Fisher & Paykel Healthcare developed a high-flow nasal cannula system compatible with multi-organ respiratory support protocols.

Conclusion :-

Integrated Organ Support Therapies are a vital advancement in critical care medicine, allowing clinicians to treat multiple failing organs with a coordinated approach. The growing prevalence of comorbid conditions, aging populations, and increased ICU admissions is driving the demand for these life-saving technologies. With global health systems focused on improving ICU efficiency and patient outcomes, IOST solutions offer a pathway to managing complexity with precision. As more hospitals adopt advanced modular systems and regulatory frameworks support innovation, the market is set to play an increasingly central role in the future of critical care.

Browse Related Reports :

[Acute On Chronic Liver Failure \(ACLF\) Market](#)

[Wearable Health Devices Market](#)

Sai Kumar

DataM Intelligence 4market Research LLP

+1 877-441-4866

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/823713990>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.